WHO WE ARE
A global leader in the development and delivery of innovative, treatment-directing information allowing providers to design patient-specific strategies that improve outcomes, increase quality and lower the cost of cancer care.
Pierian Biosciences is dedicated to profoundly changing the approach to cancer treatment for both patients and providers in an effort to deliver on the promise of personalized medicine: the right treatment, for the right patient, at the right time.
The Pierian Biosciences technology platforms are currently undergoing optimization so they will be able to deliver specific, actionable, personalized information regarding the most appropriate chemotherapeutic, biologic, and/or immunotheraputic cancer treatment for each patient.
With this valuable information, providers will be able to design patient-specific strategies that enhance the quality of life for cancer patients.
A comprehensive functional immuno-assay focused on intra-tumoral and peripheral “markers” of immune system activation and competence to guide the selection of the most appropriate immunotherapeutic. [MORE]
A functional multi-modal chemosensitivity assay providing actionable information guiding the selection of the most effective cytotoxic agent. Continuous real-time kinetic profiling of multi-parametric molecular apoptotic responses clearly differentiate ChemoINTEL from other available chemosensitivity assays. [MORE]
TARGETED AND BIOLOGIC THERAPIES
A functional proteomic profiling assay which provides quantitative information on the expression and activation status of proteins of interest to identify the true oncogenic “driver” and allow selection of the most appropriate targeted and/or biologic therapy. [MORE]
Builds Cross-Scientific Platform to Become Premier Provider of Personalized Cancer Intelligence to Improve Cancer Outcomes NASHVILLE, Tenn., September 20th, 2016 – DiaTech Holdings, Inc., the premier developer of life science technologies providing treatment directing...read more
Client: DiaTech Holdings/Pierian Biosciences, Inc. Date: September 21, 2016 Project: PR – Op-Ed: Response to New Clinical Trials Requirements from HHS Cancer deaths have declined substantially in the past decade. According to the National Cancer Institute, from 2003...read more